Blocking brain tumor rebound

Blocking indolamine 2,3 dioxygenase mediated rebound immune suppression improves systemic anti-tumor effects of radio-immunotherapy

Immunotherapy can paradoxically up-regulate immunosuppressive pathways, a phenomenon we term “rebound immunosuppression”. One such pathway is the immunosuppressive enzyme indolamine-2,3-dioxygenase (IDO). Here, we postulated that IDO blockade will improve immunotherapy efficacy by preventing rebound immune-suppression. It has been previously shown that immunotherapy consisting of intralesional ...

Blocking Tumor Necrosis Factor

O 25: Immunotherapy for Brain Tumor

In 1890, Coley observed that cancer patients who developed infections had smaller tumors. From this, he developed Coley’s toxin and treated tumors with injections of infectious materials. In 1960s,  Mahaley used monoclonal antibodies to treat central nervous system(CNS)  tumors, that research and clinical investigations in brain tumor immunotherapy became a serious undertaking. ...

Brain state dependent postinhibitory rebound in entorhinal cortex interneurons.

Postinhibitory rebound (PIR) is believed to play an important role in the genesis and maintenance of biological rhythms. While it has been demonstrated during several in vitro studies, in vivo evidence for PIR remains scarce. Here, we report that PIR can be observed in the dorsomedial entorhinal cortex of anesthetized rats, mostly between putatively connected GABAergic interneurons, and that it...

Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo.

The chemokine CXCL12 and its cognate receptor CXCR4 regulate malignant brain tumor growth and are potential chemotherapeutic targets. However, the molecular basis for CXCL12-induced tumor growth remains unclear, and the optimal approach to inhibiting CXCR4 function in cancer is unknown. To develop such a therapeutic approach, we investigated the signaling pathways critical for CXCL12 function i...